WO2009041037A1 - 体内に存在する病因物質の低下剤 - Google Patents

体内に存在する病因物質の低下剤 Download PDF

Info

Publication number
WO2009041037A1
WO2009041037A1 PCT/JP2008/002652 JP2008002652W WO2009041037A1 WO 2009041037 A1 WO2009041037 A1 WO 2009041037A1 JP 2008002652 W JP2008002652 W JP 2008002652W WO 2009041037 A1 WO2009041037 A1 WO 2009041037A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
vivo
occurring
pathogen occurring
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/002652
Other languages
English (en)
French (fr)
Inventor
Tetsuji Yamaoka
Mariko Shiba
Atsushi Mahara
Yoshihito Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
National Cerebral and Cardiovascular Center
Original Assignee
Kowa Co Ltd
National Cerebral and Cardiovascular Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, National Cerebral and Cardiovascular Center filed Critical Kowa Co Ltd
Priority to US12/679,395 priority Critical patent/US8834887B2/en
Priority to JP2009534176A priority patent/JP5429804B2/ja
Priority to EP08833835.5A priority patent/EP2191849B1/en
Publication of WO2009041037A1 publication Critical patent/WO2009041037A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　本発明は、体内中に存在する病因物質を積極的に代謝又は排泄させるための薬剤を提供することにある。 　本発明は、（Ａ）血中又はリンパ液中に存在する病因物質の吸着剤と、（Ｂ）当該原因物質を代謝又は排泄する能力を有する臓器又は細胞に特異的なリガンドとを、リンカーを介して又は介さずに結合させてなる化合物、及びこれを含有する医薬に関する。
PCT/JP2008/002652 2007-09-26 2008-09-25 体内に存在する病因物質の低下剤 Ceased WO2009041037A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/679,395 US8834887B2 (en) 2007-09-26 2008-09-25 Drug for suppressing pathogen occurring in vivo
JP2009534176A JP5429804B2 (ja) 2007-09-26 2008-09-25 体内に存在する病因物質の低下剤
EP08833835.5A EP2191849B1 (en) 2007-09-26 2008-09-25 Drug for suppressing pathogen occurring in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007249275 2007-09-26
JP2007-249275 2007-09-26

Publications (1)

Publication Number Publication Date
WO2009041037A1 true WO2009041037A1 (ja) 2009-04-02

Family

ID=40510942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002652 Ceased WO2009041037A1 (ja) 2007-09-26 2008-09-25 体内に存在する病因物質の低下剤

Country Status (4)

Country Link
US (1) US8834887B2 (ja)
EP (1) EP2191849B1 (ja)
JP (1) JP5429804B2 (ja)
WO (1) WO2009041037A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12364766B2 (en) 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US20230097887A1 (en) 2018-04-09 2023-03-30 Yale University Bi-functional Molecules to Degrade Circulating Proteins
WO2019199621A1 (en) 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
IL294515A (en) 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins
WO2022235699A2 (en) 2021-05-03 2022-11-10 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01221400A (ja) * 1987-09-14 1989-09-04 Center For Molecular Medicine & Immunolog クリアランスを向上させた修飾抗体
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
JPH06269500A (ja) * 1992-05-14 1994-09-27 Wr Grace & Co Connecticut 低密度リポタンパク質−コレステロールの除去に適した微孔性ポリスルホン担体
JPH09266948A (ja) 1996-01-31 1997-10-14 Kanegafuchi Chem Ind Co Ltd 血液浄化器および血液浄化装置
JPH11507046A (ja) * 1995-06-07 1999-06-22 イムノメディクス，インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法
JPH11509084A (ja) * 1995-06-06 1999-08-17 トランスカーヨティック セラピーズ インク． 選択された物質の細胞内への輸送に用いるためのキメラ蛋白質
JP2002504831A (ja) * 1995-11-15 2002-02-12 バクスター・インターナショナル・インコーポレイテッド 自己抗体の除去による心筋症の処置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550192A (en) 1983-09-01 1985-10-29 The Dow Chemical Company Fluorophenoxyphenoxypropionates and derivatives thereof
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5783400A (en) * 1990-04-27 1998-07-21 Genzyme Corporation Method for the isolation of lipoprotein allowing for the subsequent quantification of its mass and cholesterol content
US5418061A (en) 1990-11-27 1995-05-23 W. R. Grace & Co.-Conn. Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
AU5322494A (en) * 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
JPH08253430A (ja) 1995-03-17 1996-10-01 Kanagawa Kagaku Gijutsu Akad Ｌｄｌレセプター媒介薬物輸送方法
US6878269B2 (en) 1996-01-31 2005-04-12 Kaneka Corporation Device for body fluid purification and system for body fluid purification
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
ATE493186T1 (de) * 2001-04-10 2011-01-15 Bioe Llc Zelltrennungszusammensetzungen und -verfahren
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
JPH01221400A (ja) * 1987-09-14 1989-09-04 Center For Molecular Medicine & Immunolog クリアランスを向上させた修飾抗体
JPH06269500A (ja) * 1992-05-14 1994-09-27 Wr Grace & Co Connecticut 低密度リポタンパク質−コレステロールの除去に適した微孔性ポリスルホン担体
JPH11509084A (ja) * 1995-06-06 1999-08-17 トランスカーヨティック セラピーズ インク． 選択された物質の細胞内への輸送に用いるためのキメラ蛋白質
JPH11507046A (ja) * 1995-06-07 1999-06-22 イムノメディクス，インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法
JP2002504831A (ja) * 1995-11-15 2002-02-12 バクスター・インターナショナル・インコーポレイテッド 自己抗体の除去による心筋症の処置
JPH09266948A (ja) 1996-01-31 1997-10-14 Kanegafuchi Chem Ind Co Ltd 血液浄化器および血液浄化装置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MED. J. AUST., vol. 174, 2001, pages 459 - 466
See also references of EP2191849A4

Also Published As

Publication number Publication date
JPWO2009041037A1 (ja) 2011-01-13
US8834887B2 (en) 2014-09-16
EP2191849A1 (en) 2010-06-02
JP5429804B2 (ja) 2014-02-26
EP2191849B1 (en) 2018-08-01
US20100209441A1 (en) 2010-08-19
EP2191849A4 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
WO2007142752A3 (en) Polymer-bioceramic composite implantable medical devices
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
WO2008036206A3 (en) Copolymer-bioceramic composite implantable medical devices
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
EP2331185B8 (en) Luer activated medical connector having a low priming volume
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
EP2291509A4 (en) Microfluidic isolation of tumor cells or other rare cells from whole blood or other liquids
WO2008055037A3 (en) Infusion devices and methods
EP1949758A4 (en) IMPLANTABLE CONVERTER WITH TRANSVERSAL POWER APPLICATION
SI2081609T1 (sl) Vroče talilna lepilna masa
WO2010042948A3 (en) Tetratopic phenyl compounds, related metal-organic framework materials and post-assembly elaboration
EP2175794A4 (en) Device for the modulation of cardiac end diastolic volume
PL1733707T3 (pl) Układ kaniuli infuzyjnej
WO2009041037A1 (ja) 体内に存在する病因物質の低下剤
WO2010040772A3 (en) Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
IL190320A0 (en) Syringe assist for infusion pump
WO2008075192A3 (en) Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
WO2009040742A9 (en) Methods for imaging the blood perfusion
WO2011112566A3 (en) Basigin binding proteins
WO2010062966A3 (en) Methods for inducing mixed chimerism
WO2010066356A3 (de) Medizinische klebstoffe für die chirurgie
WO2009018967A3 (de) Kombination zum verkleben von biologischen geweben
WO2008005806A3 (en) Therapeutic methods, compositions, and compounds
WO2007041397A3 (en) Targeted pharmaceuticals and ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08833835

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009534176

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008833835

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12679395

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)